(Q44163523)

30 November 2017

Position paper on imatinib mesylate in chronic myeloid leukaemia (English)

1 reference

30 November 2017

1 reference

1 reference

Stephen G O'Brien

1

1 reference

PubMed ID

12358935

30 November 2017

Simon A J Rule

series ordinal

2

1 reference

PubMed ID

12358935

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

British Journal of Haematology

30 November 2017

1 reference

30 November 2017

119

1 reference

30 November 2017

1

1 reference

30 November 2017

268-272

1 reference

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

30 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

Chronic myeloid leukemia: current treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

ARG tyrosine kinase activity is inhibited by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.39201.X

10.1046/J.1365-2141.2002.39201.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

12358935